Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial
Katarzyna Kotulska, David J. Kwiatkowski, Paolo Curatolo, et al.
Annals of Neurology (2020) Vol. 89, Iss. 2, pp. 304-314
Open Access | Times Cited: 199

Showing 1-25 of 199 citing articles:

Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, Mary E. Aronow, E. Martina Bebin, et al.
Pediatric Neurology (2021) Vol. 123, pp. 50-66
Open Access | Times Cited: 441
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Wolfgang Löscher, Pavel Klein
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 935-963
Open Access | Times Cited: 217
International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions
Kate Riney, Alicia Bogacz, Ernest Somerville, et al.
Epilepsia (2022) Vol. 63, Iss. 6, pp. 1443-1474
Open Access | Times Cited: 168
Drug resistance in epilepsy
Emilio Perucca, Piero Perucca, H. Steve White, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 8, pp. 723-734
Closed Access | Times Cited: 107
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Adam Strzelczyk, Susanne Schubert‐Bast
CNS Drugs (2022) Vol. 36, Iss. 10, pp. 1079-1111
Open Access | Times Cited: 95
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy
Paolo Curatolo, Nicola Specchio, Eleonora Aronica
The Lancet Neurology (2022) Vol. 21, Iss. 9, pp. 843-856
Closed Access | Times Cited: 76
New epilepsy therapies in development
Pavel Klein, Rafal M. Kaminski, Matthias J. Koepp, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 682-708
Closed Access | Times Cited: 34
The Genetics of Tuberous Sclerosis Complex and Related mTORopathies: Current Understanding and Future Directions
Alice Man, Matteo Di Scipio, Shan Grewal, et al.
Genes (2024) Vol. 15, Iss. 3, pp. 332-332
Open Access | Times Cited: 18
Epilepsy in the mTORopathies: opportunities for precision medicine
Patrick B. Moloney, Gianpiero L. Cavalleri, Norman Delanty
Brain Communications (2021) Vol. 3, Iss. 4
Open Access | Times Cited: 87
The pharmacological treatment of epilepsy: recent advances and future perspectives
Emilio Perucca
Acta Epileptologica (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 63
Monogenic Epilepsies
Renzo Guerrini, Simona Balestrini, Elaine Wirrell, et al.
Neurology (2021) Vol. 97, Iss. 17, pp. 817-831
Open Access | Times Cited: 61
Recent advances in pharmacotherapy for epilepsy
Amanda W. Pong, Kevin J. Xu, Pavel Klein
Current Opinion in Neurology (2023) Vol. 36, Iss. 2, pp. 77-85
Closed Access | Times Cited: 40
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial
E. Martina Bebin, Jurriaan M. Peters, Brenda E. Porter, et al.
Annals of Neurology (2023) Vol. 95, Iss. 1, pp. 15-26
Open Access | Times Cited: 31
Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy
Nicola Specchio, Rima Nabbout, Eleonora Aronica, et al.
European Journal of Paediatric Neurology (2023) Vol. 47, pp. 25-34
Open Access | Times Cited: 28
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development
Emilio Perucca, H. Steve White, Meir Bialer
CNS Drugs (2023) Vol. 37, Iss. 9, pp. 781-795
Open Access | Times Cited: 25
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group
Djalila Mekahli, Roman‐Ulrich Müller, Matko Marlais, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 6, pp. 402-420
Open Access | Times Cited: 11
Retrospective analysis of presymptomatic treatment in Sturge–Weber syndrome
Chelsea B. Valery, Isabelle Iannotti, Eric H. Kossoff, et al.
Annals of the Child Neurology Society (2024) Vol. 2, Iss. 1, pp. 60-72
Open Access | Times Cited: 9
An overview of the value of mTOR inhibitors to the treatment of epilepsy: the evidence to date
Patrick B. Moloney, Norman Delanty
Expert Review of Neurotherapeutics (2025)
Closed Access | Times Cited: 1
Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy
Debopam Samanta
Children (2025) Vol. 12, Iss. 4, pp. 481-481
Open Access | Times Cited: 1
Early‐life epilepsy after acute symptomatic neonatal seizures: A prospective multicenter study
Renée A. Shellhaas, Courtney J. Wusthoff, Adam L. Numis, et al.
Epilepsia (2021) Vol. 62, Iss. 8, pp. 1871-1882
Open Access | Times Cited: 44
Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network
Alexander L. Cohen, Brechtje P. F. Mulder, Anna K. Prohl, et al.
Annals of Neurology (2021) Vol. 89, Iss. 4, pp. 726-739
Open Access | Times Cited: 43
Prevention of epileptogenesis – are we there yet?
Matthias J. Koepp, Eugen Trinka, Wolfgang Löscher, et al.
Current Opinion in Neurology (2024)
Closed Access | Times Cited: 8
Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine
Hannah R. Snyder, Puneet Jain, Rajesh RamachandranNair, et al.
Genes (2024) Vol. 15, Iss. 3, pp. 266-266
Open Access | Times Cited: 6
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?
Wolfgang Löscher, Pavel Klein
Pharmacology & Therapeutics (2021) Vol. 229, pp. 107934-107934
Open Access | Times Cited: 40
Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine
Susanne Schubert‐Bast, Adam Strzelczyk
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top